|
1
|
Ferlay J, Ervik M, Lam F, Laversanne M,
Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I and Bray F:
Global cancer observatory: Cancer today, Lyon, France:
International agency for research on cancer. Available from:.
https://gco.iarc.who.int/todayMarch
13–2024
|
|
2
|
Daniyal M, Siddiqui ZA, Akram M, Asif HM,
Sultana S and Khan A: Epidemiology, etiology, diagnosis and
treatment of prostate cancer. Asian Pac J Cancer Prev.
15:9575–9578. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Situmorang GR, Umbas R, Mochtar CA and
Santoso RB: Prostate cancer in younger and older patients: Do we
treat them differently? Asian Pac J Cancer Prev. 13:4577–4580.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pina F, Castro C, Ferro A, Bento MJ and
Lunet N: Prostate cancer incidence and mortality in Portugal:
Trends, projections and regional differences. Eur J Cancer Prev.
26:404–410. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Printz C: Early-stage prostate cancer, PSA
screening rates decline. Cancer. 122:8252016. View Article : Google Scholar
|
|
7
|
Sridharan S, Dal Pra A, Catton C, Bristow
RG and Warde P: Locally advanced prostate cancer: Current
controversies and optimisation opportunities. Clin Oncol.
25:499–505. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wani M and Madaan S: What is new in the
management of high-risk localized prostate cancer? J Clin Med.
12:4552023. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Khauli R, Ferrigno R, Guimarães G,
Bulbulan M, Uson Junior PLS, Salvajoli B, Palhares DMF, Racy D, Gil
E, de Arruda FF, et al: Treatment of localized and locally
advanced, high-risk prostate cancer: A report from the first
prostate cancer consensus conference for developing countries. JCO
Glob Oncol. 7:530–537. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nyberg T, Frost D, Barrowdale D, Evans DG,
Bancroft E, Adlard J, Ahmed M, Barwell J, Brady AF, Brewer C, et
al: Prostate cancer risks for male BRCA1 and BRCA2 mutation
carriers: A prospective cohort study. Eur Urol. 77:24–35. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kgatle MM, Kalla AA, Islam MM, Sathekge M
and Moorad R: Prostate cancer: Epigenetic alterations, risk
factors, and therapy. Prostate Cancer. 2016:56538622016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gathirua-Mwangi WG and Zhang J: Dietary
factors and risk of advanced prostate cancer. Eur J Cancer Prev.
23:96–109. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Adjakly M, Ngollo M, Dagdemir A, Judes G,
Pajon A, Karsli-Ceppioglu S, Penault-Llorca F, Boiteux JP, Bignon
YJ, Guy L and Bernard-Gallon D: Prostate cancer: The main risk and
protective factors-Epigenetic modifications. Ann Endocrinol
(Paris). 76:25–41. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Budäus L, Huland H and Graefen M:
Controversies in the management of localized prostate cancer:
Radical prostatectomy still the standard of care. Crit Rev Oncol
Hematol. 84 (Suppl 1):e24–e29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Popiolek M, Rider JR, Andrén O, Andersson
SO, Holmberg L, Adami HO and Johansson JE: Natural history of
early, localized prostate cancer: A final report from three decades
of follow-up. Eur Urol. 63:428–435. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Marhold M, Kramer G, Krainer M and Le
Magnen C: The prostate cancer landscape in Europe: Current
challenges, future opportunities. Cancer Lett. 526:304–310. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Evans AJ: Treatment effects in prostate
cancer. Mod Pathol. 31((S1)): S110–S121. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
ESMO, . Available at. https://www.esmo.org/for-patients/esmo-designated-centres-of-integrated-oncology-palliative-care/esmo-accredited-designated-centres/instituto-portugues-de-oncologia-do-porto-francisco-gentil-epeJanuary
12–2023
|
|
19
|
von Elm E, Altman DG, Egger M, Pocock SJ,
Gøtzsche PC and Vandenbroucke JP: STROBE: Initiative: The
strengthening the reporting of observational studies in
epidemiology (STROBE) statement: Guidelines for reporting
observational studies. Int J Surg. 12:1495–1499. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
ICD-O-3 Coding Materials Archive.
https://seer.cancer.gov/archive/icd-o-3/January
12–2023
|
|
21
|
Amin MB, Greene FL, Edge SB, Compton CC,
Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR and
Winchester DP: The eighth edition AJCC cancer staging manual:
Continuing to build a bridge from a population-based to a more
‘personalized’ approach to cancer staging. CA Cancer J Clin.
67:93–99. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mottet N, Bellmunt J, Briers E, et al:
EAU-ESTRO-ESUR-SIOG guidelines on prostate cancer. Available at.
https://uroweb.org/guidelines/prostate-cancerJanuary
12–2023
|
|
23
|
Roach M III, Hanks G, Thames H Jr,
Schellhammer P, Shipley WU, Sokol GH and Sandler H: Defining
biochemical failure following radiotherapy with or without hormonal
therapy in men with clinically localized prostate cancer:
Recommendations of the RTOG-ASTRO phoenix consensus conference. Int
J Radiat Oncol Biol Phys. 65:965–974. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
The Prostate Cancer Clinical Trials
Working Group 3, . Available at. https://pcctc.org/news/pcwg3/January 12–2023
|
|
25
|
R Core Team (2021), . R: A language and
environment for statistical computing. R foundation for statistical
computing Vienna, Austria: Available at. https://www.R-project.org/April 18–2024
|
|
26
|
Botelho F, Lopes R, Pina F, Silva C,
Pacheco-Figueiredo L and Lunet N: Prostate cancer treatment in
Portugal: A nationwide analysis. Sci Rep. 13:193622023. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
George DJ, Sartor O, Miller K, Saad F,
Tombal B, Kalinovský J, Jiao X, Tangirala K, Sternberg CN and
Higano CS: Treatment patterns and outcomes in patients with
metastatic castration-resistant prostate cancer in a real-world
clinical practice setting in the United States. Clin Genitourin
Cancer. 18:284–294. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li PI, Chen SJ, Chen YH, Chen WC and Huang
CP: Comparative outcomes of robotic radical prostatectomy in
patients with locally advanced prostate cancer. Medicina (Kaunas).
58:18202022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pereira-Lourenço M, Vieira E, Brito D,
Peralta JP, Godinho R, Conceiçao P, Reis M, Rabaça C and Sismeiro
A: Influence of sociodemographic factors on treatment's choice for
localizd prostate cancer in Portugal. Arch Ital Urol Androl.
92:45–49. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nunes P, Pimentel FL, Pina F and Rolo F:
National registry of prostate cancer, in Portugal-ReNaCaP. Acta
Urologica. 3:39–45. 2010.
|
|
31
|
Galego P, Silva FC and Pinheiro LC:
Analysis of monotherapy prostate brachytherapy in patients with
prostate cancer. Initial PSA and Gleason are important for
recurrence? Int Braz J Urol. 41:353–359. 2015.PubMed/NCBI
|
|
32
|
Ash D, Flynn A, Battermann J, Reijke T,
Lavagnini P and Blank L; ESTRA/EAU Urological Brachytherapy Group
and EORTC Radiotherapy Group, : ESTRO/EAU/EORTC recommendations on
permanent seed implantation for localized prostate cancer.
Radiother Oncol. 57:315–321. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Goy BW and Burchette R: Ten-year treatment
complication outcomes of radical prostatectomy vs external beam
radiation vs brachytherapy for 1503 patients with intermediate risk
prostate cancer. Brachytherapy. 20:1083–1089. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Braga I, Monteiro S, Calisto R, Rangel M,
Medeiros E, Cunha JS, Rosinha A, Oliveira A, Bento MJ, Lopes R, et
al: Healthcare resource utilization (HCRU) in treatment of patients
with localized/locally advanced prostate cancer (LPC/LAPC) in a
Portuguese comprehensive cancer center (PCCC). Value in Health.
25:S2802022. View Article : Google Scholar
|
